Novo Nordisk | NVO - Selling And Administration Expenses


Novo Nordisk reported DKK2.86B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bausch Health Companies USD 813M 12M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Zoetis USD 588M 31M Mar/2026